Sue Browne - Passage Bio Senior Development
| PASG Stock | USD 0.75 0.08 11.94% |
Executive
Sue Browne is Senior Development of Passage Bio
| Address | One Commerce Square, Philadelphia, PA, United States, 19103 |
| Phone | 267 866 0311 |
| Web | https://www.passagebio.com |
Passage Bio Management Efficiency
The company has return on total asset (ROA) of (0.3448) % which means that it has lost $0.3448 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.6355) %, meaning that it created substantial loss on money invested by shareholders. Passage Bio's management efficiency ratios could be used to measure how well Passage Bio manages its routine affairs as well as how well it operates its assets and liabilities. The current Return On Tangible Assets is estimated to decrease to -0.71. The current Return On Capital Employed is estimated to decrease to -0.85. At this time, Passage Bio's Total Current Assets are most likely to increase significantly in the upcoming years.Similar Executives
| Showing other executives | EXECUTIVE Age | ||
| RPh Young | Seres Therapeutics | 57 | |
| MD FAAP | Lumos Pharma | N/A | |
| SPHR SHRMSCP | Seres Therapeutics | 52 | |
| Lisa MD | Seres Therapeutics | 65 | |
| Kim Fox | Milestone Pharmaceuticals | N/A | |
| Valdas Jurkauskas | Ikena Oncology | N/A | |
| Eddie MBA | Lumos Pharma | N/A | |
| Roshan Girglani | Milestone Pharmaceuticals | N/A | |
| Rachael Nokes | Scpharmaceuticals | 49 | |
| Jeffrey Nelson | Milestone Pharmaceuticals | 43 | |
| Carlo Tanzi | Seres Therapeutics | N/A | |
| David Ege | Seres Therapeutics | 49 | |
| MD MBA | Eliem Therapeutics | 50 | |
| Samuel MD | Tempest Therapeutics | 58 | |
| Ryan Witt | RenovoRx | N/A | |
| Nishi MD | Eliem Therapeutics | N/A | |
| Caroline MD | Ikena Oncology | 52 | |
| JD Esq | Seres Therapeutics | 69 | |
| Matthew Henn | Seres Therapeutics | 49 | |
| David MS | Ikena Oncology | N/A | |
| Lindsay Young | Tempest Therapeutics | N/A | |
Management Performance
| Return On Equity | -0.64 | ||||
| Return On Asset | -0.34 |
Passage Bio Leadership Team
Elected by the shareholders, the Passage Bio's board of directors comprises two types of representatives: Passage Bio inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Passage. The board's role is to monitor Passage Bio's management team and ensure that shareholders' interests are well served. Passage Bio's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Passage Bio's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Sue Browne, Senior Development | ||
| William MD, CEO President | ||
| Simona King, CFO Sec | ||
| JD Esq, General Secretary | ||
| Gregory Fuest, Vice Marketing | ||
| MSc MBA, Chief Officer | ||
| Kathleen Borthwick, Principal Finance | ||
| Stuart Henderson, Senior Relations | ||
| Eden Fucci, Senior Operations | ||
| Karl Whitney, Senior Affairs | ||
| Mark MD, Chief Officer | ||
| David MD, VP Devel | ||
| Desiree DDS, VP Affairs |
Passage Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Passage Bio a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.64 | ||||
| Return On Asset | -0.34 | ||||
| Current Valuation | (12.62 M) | ||||
| Shares Outstanding | 61.77 M | ||||
| Shares Owned By Insiders | 0.49 % | ||||
| Shares Owned By Institutions | 59.68 % | ||||
| Number Of Shares Shorted | 1.63 M | ||||
| Price To Book | 0.64 X | ||||
| EBITDA | (98.34 M) | ||||
| Net Income | (102.06 M) |
Currently Active Assets on Macroaxis
When determining whether Passage Bio is a strong investment it is important to analyze Passage Bio's competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Passage Bio's future performance. For an informed investment choice regarding Passage Stock, refer to the following important reports:Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Passage Bio. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in state. For more detail on how to invest in Passage Stock please use our How to Invest in Passage Bio guide.You can also try the My Watchlist Analysis module to analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Passage Bio. If investors know Passage will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Passage Bio listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.04) | Return On Assets (0.34) | Return On Equity (0.64) |
The market value of Passage Bio is measured differently than its book value, which is the value of Passage that is recorded on the company's balance sheet. Investors also form their own opinion of Passage Bio's value that differs from its market value or its book value, called intrinsic value, which is Passage Bio's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Passage Bio's market value can be influenced by many factors that don't directly affect Passage Bio's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Passage Bio's value and its price as these two are different measures arrived at by different means. Investors typically determine if Passage Bio is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Passage Bio's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.